Ninety-three million dollars for a molecule that has not yet filed an IND is a meaningful signal about where retinal disease investment is heading, and the Tie2 receptor is the reason why. Memento Medicines launched this week with that Series A, co-led by Forbion, RA Capital Management, and Avego BioScience Capital, to advance MMT-205, a bispecific antibody licensed from Korean biotechs MabTics and Curacle. The asset combines direct Tie2 agonism with VEGF inhibition, targeting a combined nAMD and DME market valued in the billions, both indications long managed with frequent intravitreal anti-VEGF injections.
The strategic logic here is straightforward but not simple. Anti-VEGF monotherapies like aflibercept have been foundational in nAMD and DME for over a decade, delivering meaningful visual acuity gains in pivotal trials. The ceiling on those gains, however, is well-documented. Tie2 is a vascular stabilization target that VEGF inhibition alone does not engage, and the preclinical case for combining the two pathways is that you get better vascular integrity on top of the anti-permeability effect. Memento’s own preclinical data reportedly shows greater Tie2 activation and improved retinal vascular integrity with MMT-205 compared to current agents, though those claims await clinical testing. IND-enabling work is the immediate use of proceeds, with trials expected in 2027.
What sharpens the competitive picture is that Memento is not the only party betting on bispecific Tie2/VEGF biology. Merck’s MK-8748 (Tiespectus) has already advanced into a pivotal Phase 2b/3 trial in nAMD, validating the mechanism but also raising the bar for a company still in IND-enabling mode. Memento enters a field where the biology is no longer speculative, which helps fundraising, but also means differentiation will ultimately rest on clinical data: dosing interval, durability, and the magnitude of Tie2 engagement. Sanofi Ventures joining the syndicate alongside the three co-leads adds a strategic dimension worth noting, given Sanofi’s existing ophthalmology footprint.
Memento is also the fifth subsidiary financed through RA Capital’s Sera Medicines accelerator, a structure designed to compress the time between asset identification and capitalization. The number to watch as this program matures is not the Series A size but the IND filing date: whether Memento hits its 2027 clinical start will determine whether it enters Phase 1 with a defined lead or chases a field that has already begun generating registrational data.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
